%0 Journal Article %T A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %D 2015 %\ 12/01/2015 %V 16 %N 14 %P 5963-5966 %! A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer %K Gemcitabine and nedaplatin %K non-small cell lung cancer %R %X Background: This analysis was conducted to evaluate the efficacy and safety of a combination of gemcitabineand nedaplatin in treating patients with non-small cell lung cancer. Methods: Clinical studies evaluating theefficacy and safety of a combination of gemcitabine and nedaplatin with attention to response and safety forpatients with non-small cell lung cancer were identified using a predefined search strategy. Pooled responserates for gemcitabine and nedaplatin were calculated. Results: In gemcitabine and nedaplatin based regimens, 4clinical studies including 112 patients with non-small cell lung cancer were considered eligible for inclusion. Thepooled analysis suggested that the pooled reponse rate was 40.2% (45/112). Main side effects included grade 3-4neutropenia, thrombocytopenia, and anemia. Grade 3-4 nonhematological toxicity included nausea and vomiting,diarrhea, and hepatic dysfunction. There were no treatment-related deaths. Conclusion: This evidence basedanalysis suggests that the combination of gemcitabine and nedaplatin is associated with good response rate andaccepted toxicity for treating patients with non-small cell lung cancer. %U https://journal.waocp.org/article_31355_5af1f26a7c12f9659e11d4baba76506a.pdf